| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
20 Nov 2024 3:18PM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
20 Nov 2024 3:17PM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
20 Nov 2024 3:17PM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
20 Nov 2024 3:16PM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Notification regarding unquoted securities - TRJ
|
20 Nov 2024 3:07PM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Results of 2024 Annual General Meeting
|
29 Oct 2024 12:02PM |
$1.260 |
$0.400 |
fallen by
68.25%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Business Update
|
29 Oct 2024 9:13AM |
$1.200 |
$0.400 |
fallen by
66.67%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Net Revenue up high single digit over prior comparative period.
- Capital Equipment food sector demonstrating strong growth contributing to total Segment revenue up 15% in Q1 over prior comparative period.
- Order demand increasing for Trajan’s MOSH/MOAH food safety instrument systems.
- US FDA purchased Trajan’s MOSH/MOAH instrument system in Q1.
- Pharmaceutical Sector continues to be soft.
- Single digit growth in Components and Consumables over prior comparative period.
- FY2025 Guidance maintained; Net Revenue of $160.0M to $165.0M, Group nEBITDA of $17.0 to $19.0M.
- Completion of small acquisition of Mass Spec Studio data processing software platform from University of Calgary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
2024 Annual General Meeting Chair Address and Presentation
|
29 Oct 2024 9:10AM |
$1.200 |
$0.400 |
fallen by
66.67%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Notification regarding unquoted securities - TRJ
|
28 Oct 2024 10:05AM |
$1.210 |
$0.400 |
fallen by
66.94%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
2024 Notice of Annual General Meeting
|
26 Sep 2024 5:22PM |
$1.250 |
$0.400 |
fallen by
68%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
20 Sep 2024 5:21PM |
$1.245 |
$0.400 |
fallen by
67.87%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
3 Sep 2024 11:30AM |
$1.200 |
$0.400 |
fallen by
66.67%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Application for quotation of securities - TRJ
|
3 Sep 2024 11:25AM |
$1.200 |
$0.400 |
fallen by
66.67%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
2024 Annual General Meeting
|
29 Aug 2024 8:06AM |
$1.150 |
$0.400 |
fallen by
65.22%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY24 Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 8:06AM |
$1.150 |
$0.400 |
fallen by
65.22%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY24 Financial Results Presentation
|
29 Aug 2024 8:06AM |
$1.150 |
$0.400 |
fallen by
65.22%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Extraordinary industry-wide issues impacted TRJ’s FY24 result, particularly during H1 with destocking in the Components & Consumables Segment, and in H2 with a slowdown in pharmaceutical sector capital equipment orders.
- Net revenue was slightly down with $155.0M in FY24 compared to $162.2M in FY23.
- nEBITDA Core decreased from $23.9M in FY23 to $17.2M in FY24.
- Commercialization of products within the Disruptive Technologies segment is progressing, with the Microsampling portfolio to be nEBITDA breakeven in FY25.
- Net profit after tax plus amortization (NPATA) was $0.6M in FY24, down from $5.8M in FY23.
- Proforma Gross Margin decreased slightly from 43.2% in FY23 to 41.1% in FY24 due to under-utilization of manufacturing infrastructure.
- Revenue and nEBITDA in H2 showed improvement over H1, returning to growth.
- Financial guidance for the upcoming year includes expected net revenue of $160.0M-$165.0M and nEBITDA of $17.0M-$19.0M.
- The company anticipates Components & Consumables to continue at historical growth rates post-destocking, and Capital Equipment demand within the pharmaceutical sector to return to typical order demand in CY25.
- Trajan Group Holdings Limited emphasizes a robust business model, high barriers to market entry, and long-term shareholder value focus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY24 Financial Results Release
|
29 Aug 2024 8:06AM |
$1.150 |
$0.400 |
fallen by
65.22%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Rebounded performance in the second half with Core nEBITDA up 48.7% on H1
- Full Year Net Revenue $155.0M, within 5% of the previous year
- Core nEBITDA at $17.2M, exceeding guidance
- Destocking activities by key customers in H1 placed strain on business
- Improved revenue in Components & Consumables and Disruptive Technologies in H2
- Capital Equipment segment experienced softer demand, expected to persist in H1 FY25
- Net Debt reduction of $4.7M to $32.9M
- Proforma Gross Margin for FY24 at 41.1%
- Guidance for FY25 Net Revenue is $160.0M to $165.0M, and Group nEBITDA $17.0M to $19.0M
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY24 Appendix 4E and Annual Report
|
29 Aug 2024 8:06AM |
$1.150 |
$0.400 |
fallen by
65.22%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited reported a net revenue of $155.0 million for FY24.
- The company achieved a normalised EBITDA of $17.2 million.
- Proforma gross margin stood at 41.1%.
- Revenue for the Components & Consumables segment increased by approximately 25% in the third and fourth quarters compared to the first quarter.
- Significant progress was made in new technologies, including over 40% growth in Emitter Tips for Mass Spectrometry and a 140% increase in microbiopsy devices supplied for investigational use.
- Trajan's ESG program includes partnering with Carbonhound to establish a carbon emissions baseline and developing a 2024 ESG Strategy.
- The Capital Equipment segment reported a net revenue of $53.9 million and a normalised EBITDA of $9.7 million.
- Trajan launched its first environmental workflow solution, the CHRONECT Workstation, in August 2024.
- The company's efforts toward sustainability include redesigning sustainable packaging solutions and focusing on reducing emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Ceasing to be a substantial holder
|
19 Aug 2024 4:10PM |
$1.140 |
$0.400 |
fallen by
64.91%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY24 Full Year Results and Investor Webinar Notification
|
13 Aug 2024 12:51PM |
$1.055 |
$0.400 |
fallen by
62.09%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Non-cash intangible asset impairment, FY guidance confirmed
|
1 Aug 2024 10:02AM |
$1.055 |
$0.400 |
fallen by
62.09%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited announced a non-cash impairment of intangible assets.
- The impairment is due to a $26.7M write-down, mainly related to Neoteryx goodwill and intangibles ($25.0M).
- The remaining $1.7M impairment relates to other microsampling related assets.
- Despite the impairment, there is a strong order demand for microsampling with a 29.8% increase in H2 over H1.
- The impairment will be recorded in the Full Year 2024 Financial Results, to be released on 29th August 2024.
- A technical breach of a financial covenant occurred due to the Neoteryx impairment but has since been resolved.
- The company's performance remains aligned with the financial guidance ranges provided in May.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
29 Jul 2024 4:04PM |
$1.045 |
$0.400 |
fallen by
61.72%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
10 Jul 2024 5:42PM |
$1.040 |
$0.400 |
fallen by
61.54%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Notification of cessation of securities - TRJ
|
1 Jul 2024 9:45AM |
$1.025 |
$0.400 |
fallen by
60.98%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
14 Jun 2024 5:12PM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|